Phoenixpharmalabs

Phoenix Pharma Labs develops drugs with unique opioid receptor characteristics that provide potent pain relief (100X potency of morphine) without producing the euphoric 'high' that leads to abuse and addiction, addressing pain, addiction treatment, and PTSD.

The company has raised more than $23 million to date from grants from the U.S. Army and NIH/NIDA, equity investment, and investment in kind, and is advancing PPL-138 into Phase I human clinical trials.